COVID-19 reinfection

REINFECTION with any of SARS-COV-2 virus including SARS-COV-2 VARIANTS following a recovery from COVID-19. COVID-19 reinfection is due to second infection instead of reactivation or relapse of initial infection in COVID-19 REBOUND.

Also Known As:

Networked: 18 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Reinfection
2.	COVID-19
3.	Vasculitis (Vasculitides)
4.	Myocarditis (Carditis)
5.	Infections

Experts

1.	Ishikane, Masahiro: 3 articles (11/2022 - 07/2021)
2.	Ishizaka, Yukihito: 3 articles (11/2022 - 07/2021)
3.	Maeda, Kenji: 3 articles (11/2022 - 07/2021)
4.	Matsunaga, Akihiro: 3 articles (11/2022 - 07/2021)
5.	Mitsuya, Hiroaki: 3 articles (11/2022 - 07/2021)
6.	Ohmagari, Norio: 3 articles (11/2022 - 07/2021)
7.	Inada, Makoto: 2 articles (06/2022 - 07/2021)
8.	Kutsuna, Satoshi: 2 articles (06/2022 - 07/2021)
9.	Terada, Mari: 2 articles (06/2022 - 07/2021)
10.	Ujiie, Mugen: 2 articles (06/2022 - 07/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to COVID-19 reinfection:

1.	VaccinesIBA 12/15/2022 - "The findings of this study suggest that vaccines can offer short-term protection against COVID-19 reinfection. " 01/01/2021 - "COVID-19 reinfection: the role of natural immunity, vaccines, and variants." 06/01/2023 - "With the now high prevalence of prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we assessed the effect of prior infection on the vaccine risk and the risk from COVID-19 reinfection. " 12/01/2021 - "As the COVID-19 pandemic rages on, reports on disparities in vaccine roll out alongside COVID-19 reinfection have been emerging. " 06/01/2022 - "Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection."
2.	AntibodiesIBA 09/12/2021 - "Conclusions: Virus-specific antibodies had a protective effect against COVID-19 reinfection for the majority of the population, however, this effect may decrease over time. " 11/01/2021 - "Humoral antibodies against SARS-CoV-2 were protective against COVID-19 reinfection, 0.8% of the patients had reinfection and the resultant reinfection was mostly seen in PCR negative patients who were asymptomatic." 11/01/2022 - "In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. " 11/01/2022 - "Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. "
3.	Immunosuppressive Agents (Immunosuppressants)IBA 10/01/2022 - "This pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/immunomodulating agents. " 10/01/2022 - "The objective of this study was to characterize cases indicative of COVID-19 reinfection with respect to their reported use of immunosuppressant/immunomodulating agents. " 10/01/2022 - "Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database." 10/01/2022 - "Of these 4590 cases of potential Covid-19 reinfection, a total of 134 cases reported COVID-19 specifically during treatment with pharmaceutical products, of which approximately 16% (21/134) of cases reported use of immunosuppressant/immunomodulating agents. "
4.	Immunomodulating AgentsIBA 10/01/2022 - "This pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/immunomodulating agents. " 10/01/2022 - "The objective of this study was to characterize cases indicative of COVID-19 reinfection with respect to their reported use of immunosuppressant/immunomodulating agents. " 10/01/2022 - "Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database." 10/01/2022 - "Of these 4590 cases of potential Covid-19 reinfection, a total of 134 cases reported COVID-19 specifically during treatment with pharmaceutical products, of which approximately 16% (21/134) of cases reported use of immunosuppressant/immunomodulating agents. "
5.	Neutralizing AntibodiesIBA 07/01/2021 - "Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies." 04/01/2021 - "COVID-19 reinfection in the presence of neutralizing antibodies."
6.	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/01/2021 - "COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis."
7.	CytokinesIBA 01/01/2022 - "Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-Adsorbing oXiris® Hemofilter Continuous Veno-Venous Hemofiltration and Extracorporeal Membrane Oxygenation."
8.	Indicators and Reagents (Reagents)IBA 04/01/2021 - "Anosmia: A Clinical Indicator of COVID-19 Reinfection."
9.	Immunoglobulin G (IgG)IBA 01/01/2022 - "Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection."
10.	2019-nCoV Vaccine mRNA-1273IBA 06/01/2022 - "Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection."

Therapies and Procedures

1.	Liver Transplantation 05/09/2021 - "We describe a scenario of presumed COVID-19 re-infection in a liver transplant patient. " 05/09/2021 - "We present a case of COVID-19 re-infection in a chronically immunocompromised liver transplant patient. " 05/09/2021 - "A Case of COVID-19 Re-Infection in a Liver Transplant Patient."
2.	Extracorporeal Membrane Oxygenation 01/01/2022 - "Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-Adsorbing oXiris® Hemofilter Continuous Veno-Venous Hemofiltration and Extracorporeal Membrane Oxygenation."
3.	Renal Dialysis (Hemodialysis) 11/01/2022 - "A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection." 11/01/2022 - "In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. " 11/01/2022 - "Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. "
4.	Continuous Renal Replacement Therapy 01/01/2022 - "Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-Adsorbing oXiris® Hemofilter Continuous Veno-Venous Hemofiltration and Extracorporeal Membrane Oxygenation."